19 August 201907:00 BST
AstraZeneca appoints Michel Demaré to its Board of Directors
AstraZeneca today announced that, with effect from 1 September 2019, Michel Demaré is appointed as a Non-Executive Director and a member of the Audit Committee.
Leif Johansson, Chairman of AstraZeneca, said: "We are delighted to appoint Michel Demaré as a Director. He has a great deal of industrial, financial and board-level experience across a range of sectors including science and technology, that will enable him to contribute well to the work of our Board and Audit Committee."
Michel Demaré is a Non-Executive Director of Vodafone Group Plc and a member of the Supervisory Board of Louis Dreyfus Company Holdings BV. He is Vice-Chairman and Chairman-designate of the IMD executive business school in Lausanne, and a member of the Advisory Board of the Department of Banking and Finance at the University of Zurich.
Mr Demaré was Vice-Chairman of UBS Group AG from 2010 to 2019, Chairman of Syngenta and the Syngenta Foundation for Sustainable Agriculture from 2013 to 2017 and Chairman of SwissHoldings from 2013 to 2015.
Mr Demaré joined ABB Ltd in 2005 as Chief Financial Officer (CFO) and member of the Group Executive Committee. For most of 2008, he acted as the interim Chief Executive Officer of ABB. From late 2008 to 2011, he combined his role as CFO with that of President of Global Markets.
He joined ABB from Baxter International Inc., where he was CFO Europe from 2002 to 2005. Prior to that, he spent 18 years at the Dow Chemical Company, holding various treasury and risk management positions in Belgium, France, the US and Switzerland. Between 1997 and 2002, Mr Demaré was CFO of the Global Polyolefins and Elastomers division. He began his career as a banking officer in the multinational banking division of Continental Illinois' Belgian subsidiary.
Mr Demaré graduated with an MBA from the Katholieke Universiteit Leuven, Belgium, and holds a degree in applied economics from the Université Catholique de Louvain, Belgium.
Except as set out above, no disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com (http://www.astrazeneca.com/) and follow us on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Thomas Kudsk +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer BioPharmaceuticals +44 203 749 5711
Nick Stone BioPharmaceuticals +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Corporate access, +44 203 749 5824
Kretzmann retail investors
US toll-free +1 866 381 72 77
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
(c) 2019 Cision. All rights reserved., source Press Releases - English